Drug Therapies for Fibromyalgia II

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 9332

Special Issue Editor

Department of Biosciences and Chemistry, Biomolecular Sciences Research Centre, Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK
Interests: fibromyalgia; pain; potassium channels; drug design/discovery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 1990 the American College of Rheumatology developed the criteria for the classification of fibromyalgia, a common complex persistent widespread pain condition. Treatment is often difficult, usually involving an empiric approach to drug therapy focused towards the individual symptoms of pain, fatigue, sleep disorder and cognitive dysfunction. Current medications are often limited in their effectiveness due to patients discontinuing use as a consequence of a high incidence of adverse effects. Drugs targeting a diverse range of molecular mechanisms have demonstrated modest improvement of health status in patients with fibromyalgia. Thus, the heterogeneity of fibromyalgia, suggesting existence of patient subgroups, central and peripheral aspects of the pathophysiology and a requirement of treatments targeting multiple molecular dysfunction need to be considered in the identification of new or improved therapies for the condition. We aim to invite original or review articles of preclinical and clinical findings contributing to the understanding of drug therapies for the treatment of fibromyalgia.

Dr. Kim Lawson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Related Special Issue: "Drug Therapies for the Treatment of Fibromyalgia"

Keywords

  • Fibromyalgia
  • Pain
  • Fatigue
  • Cognitive dysfunction
  • Central sensitization
  • Drug targets
  • Novel molecular mechanisms
  • Fibromyalgia animal models

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1822 KiB  
Article
Wnt/β-Catenin Pathway in Experimental Model of Fibromyalgia: Role of Hidrox®
by Ramona D’Amico, Marika Cordaro, Rosalba Siracusa, Daniela Impellizzeri, Angela Trovato Salinaro, Maria Scuto, Maria Laura Ontario, Roberto Crea, Salvatore Cuzzocrea, Rosanna Di Paola, Roberta Fusco and Vittorio Calabrese
Biomedicines 2021, 9(11), 1683; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines9111683 - 13 Nov 2021
Cited by 9 | Viewed by 1984
Abstract
Fibromyalgia (FM) is a chronic condition characterized by persistent widespread pain that negatively affects the quality of life of patients. The WNT/β-catenin signaling pathway seems to be involved in central sensitization and different pain states. The objective of this study was to investigate [...] Read more.
Fibromyalgia (FM) is a chronic condition characterized by persistent widespread pain that negatively affects the quality of life of patients. The WNT/β-catenin signaling pathway seems to be involved in central sensitization and different pain states. The objective of this study was to investigate the beneficial effects of a new compound called Hidrox® (HD), containing 40–50% hydroxytyrosol, in counteracting the pain associated with FM. An FM-like model was induced in rats by subcutaneous injections of reserpine (1 mg/kg) for three consecutive days. Later, HD (10 mg/kg) was administered orally to the animals for seven days. Reserpine injections induced WNT/β-catenin pathway activation, release of pro-inflammatory mediators as well as a significant increase in oxidative stress. Daily treatment with HD was able to modulate the WNT/β-catenin and Nrf2 pathways and consequently attenuate the behavioral deficits and microglia activation induced by reserpine injection. These results indicate that nutritional consumption of HD can be considered as a new therapeutic approach for human FM. Full article
(This article belongs to the Special Issue Drug Therapies for Fibromyalgia II)
Show Figures

Figure 1

Review

Jump to: Research

12 pages, 877 KiB  
Review
Key Milestones Contributing to the Understanding of the Mechanisms Underlying Fibromyalgia
by Geoffrey Littlejohn and Emma Guymer
Biomedicines 2020, 8(7), 223; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines8070223 - 17 Jul 2020
Cited by 16 | Viewed by 6675
Abstract
The promulgation of the American College of Rheumatology (ACR) 1990 criteria for fibromyalgia (FM) classification has significantly contributed to an era of increased research into mechanisms that underlie the disorder. The previous emphasis on putative peripheral nociceptive mechanisms has advanced to identifying of [...] Read more.
The promulgation of the American College of Rheumatology (ACR) 1990 criteria for fibromyalgia (FM) classification has significantly contributed to an era of increased research into mechanisms that underlie the disorder. The previous emphasis on putative peripheral nociceptive mechanisms has advanced to identifying of changes in central neural networks that modulate pain and other sensory processes. The influences of psychosocial factors on the dynamic and complex neurobiological mechanisms involved in the fibromyalgia clinical phenotype are now better defined. This review highlights key milestones that have directed knowledge concerning the fundamental mechanisms contributing to fibromyalgia. Full article
(This article belongs to the Special Issue Drug Therapies for Fibromyalgia II)
Show Figures

Graphical abstract

Back to TopTop